Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
Status:
Terminated
Trial end date:
2019-03-05
Target enrollment:
Participant gender:
Summary
Hepatocellular Carcinoma (HCC) is a major health concern in the United States, particularly
among people with liver cirrhosis. Out of every 100 patients with liver cancer, only 18 will
survive 5 years or more. While locoregional therapies are utilized in an effort to combat
this disease, the recurrence rate of HCC after these therapies are high.
Statins are widely used drugs that lower cholesterol levels. Some studies have suggested that
statins lower risk of HCC recurrence, but this possibility has not been studied thoroughly in
a clinical trial. This study will examine the effects of pravastatin, a type of statin, on
time to HCC recurrence in patients with early stage HCC. It is possible that pravastatin in
combination with locoregional therapies may delay or protect against HCC recurrence.
Phase:
Phase 2
Details
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)